Domingues, Neuza https://orcid.org/0000-0002-2073-412X
Calcagni’, Alessia https://orcid.org/0000-0002-1946-5815
Freire, Sofia https://orcid.org/0009-0002-2316-1096
Pires, Joana
Casqueiro, Ricardo https://orcid.org/0000-0001-8808-9756
Salazar, Ivan L https://orcid.org/0000-0001-9667-6766
Herz, Niculin Joachim
Huynh, Tuong https://orcid.org/0000-0002-5595-419X
Wieciorek, Katarzyna
Outeiro, Tiago Fleming https://orcid.org/0000-0003-1679-1727
Girão, Henrique https://orcid.org/0000-0002-5786-8447
Milosevic, Ira https://orcid.org/0000-0001-6440-3763
Ballabio, Andrea https://orcid.org/0000-0003-1381-4604
Raimundo, Nuno https://orcid.org/0000-0002-5988-9129
Funding for this research was provided by:
MEC | Fundação para a Ciência e a Tecnologia (2022.09311.PTDC)
NCL-Stiftung
EC | European Research Council
Wellcome Trust (224361/Z/21/Z)
'la Caixa' Foundation
John Black Foundation
HHS | National Institutes of Health (R01-CA260205)
Deutsche Forschungsgemeinschaft (SFB1190-P02)
Fondazione Telethon (337327)
Associazione Italiana per la Ricerca sul Cancro A.I.R.C (IG-22103)
European Research Council Advanced (H2023 AdG; INCANTAR 101097752)
EC | Horizon 2020 Framework Programme (857524)
Comissão de Coordenação e Desenvolvimento Regional do Centro - CCDRC through the Centro2020 Programme
Article History
Received: 15 April 2025
Revised: 17 September 2025
Accepted: 2 October 2025
First Online: 6 November 2025
Disclosure and competing interests statement
: A. Ballabio is cofounder and shareholder of Casma Therapeutics and was an advisory board member of Avilar Therapeutics and Amplify Therapeutics.